


## Data Sheet

<b>Product Name:</b>	SC-236
<b>Cat. No.:</b>	CS-W011699
<b>CAS No.:</b>	170569-86-5
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>11</sub> ClF <sub>3</sub> N <sub>3</sub> O <sub>2</sub> S
<b>Molecular Weight:</b>	401.79
<b>Target:</b>	Apoptosis; COX; PPAR
<b>Pathway:</b>	Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
<b>Solubility:</b>	DMSO : 100 mg/mL (ultrasonic)



### BIOLOGICAL ACTIVITY:

SC-236 is an orally active **COX-2** specific inhibitor (**IC<sub>50</sub>** = 10 nM) and a **PPAR $\gamma$**  agonist. SC-236 suppresses activator protein-1 (**AP-1**) through c-Jun NH<sub>2</sub>-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model<sup>[1][2][3][4][5]</sup>. *In Vitro*: SC-236 (15  $\mu$ M, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS<sup>[1]</sup>.

SC-236 significantly induces PPAR $\gamma$  expression in HSCs and acted as a potent PPAR $\gamma$  agonist in a luciferase-reporter trans-activation assay<sup>[2]</sup>.

SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage viability<sup>[2]</sup>.

SC-236, either alone or in combination with 15d-PGJ<sub>2</sub>, induced a marked pro-apoptotic effect in HSCs in culture<sup>[2]</sup>.

SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway<sup>[3]</sup>.

*In Vivo*: SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl<sub>4</sub>- treated animals<sup>[2]</sup>.

### References:

[1]. Shao-Yu Fang, et al. Reduction in MicroRNA-4488 Expression Induces NF $\kappa$ B Translocation in Venous Endothelial Cells Under Arterial Flow. Cardiovasc Drugs Ther. 2020 Sep 9.

[2]. Anna Planagumà, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPAR $\gamma$  activation. FASEB J. 2005 Jul;19(9):1120-2.

[3]. Benjamin Chun-Yu Wong, et al. Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH<sub>2</sub>-terminal kinase. Gastroenterology. 2004 Jan;126(1):136-47.

[4]. Su-Jin Kim, et al. The COX-2 inhibitor SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model. Life Sci. 2007 Aug 23;81(11):863-72.

[5]. T D Penning, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997 Apr 25;40(9):1347-65.

### CAIndexNames:

Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-

**SMILES:**

O=S(C1=CC=C(N2N=C(C(F)F)F)C=C2C3=CC=C(Cl)C=C3)C=C1)(N)=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA